TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03387267

Intervention type: DEVICE
Group type: OTHER
Intervention: Dysphagia Detection System
Description: The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
Study: NCT03889925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Description: Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma
Description: Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
Study: NCT04420000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness based programme
Study: NCT03586869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-HER2
Study: NCT04420000

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study: NCT03173807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and exercise guidance and modifications
Description: Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and exercise guidance and modifications
Description: Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
Study: NCT03586869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1
Study: NCT00116779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
Study: NCT01811121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolévulinique acid (5-ALA)
Description: oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
Study: NCT03586869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Carcinoembryonic Antigen (CEA) yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast
Study: NCT01811121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
Study: NCT04682210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5mg/kg IV Q3W
Study: NCT02548117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Subjects will take 5 mg finasteride orally every day for about 2 years.
Study: NCT02962115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid Invitation
Description: electronic invitation to complete web-based decision aid
Study: NCT03033069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brexpiprazole Matching Placebo
Description: Brexpiprazole matching placebo oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole Matching Placebo
Description: Brexpiprazole matching placebo oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Matching Placebo
Description: Sertraline matching placebo oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Matching Placebo
Description: Sertraline matching placebo oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline Matching Placebo
Description: Sertraline matching placebo oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline Matching Placebo
Description: Sertraline matching placebo oral capsules.
Study: NCT00874042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with ARQ 197 in combination with gemcitabine
Description: Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest.
Study: NCT03586869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT04211688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Schema therapy
Description: Bimonthly outpatient psychotherapy delivered in individual setting
Study: NCT03586869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03943407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyclara 3.75 % Topical Cream
Description: The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyclara 3.75 % Topical Cream
Description: The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
Study: NCT03586869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study: NCT04116229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
Study: NCT04116229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
Study: NCT01581346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
Study: NCT03003676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD1 blockade
Study: NCT04151862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tight eye bandage
Description: sterile eye pad made of 100% cotton

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soflex Soft Contact Lens
Description: Therapeutic contact lenses (TCL)
Study: NCT02044081

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Rinse
Description: Active rinses are 1.6 mg/mL C16G2.

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Rinse
Description: Active rinses are 1.6 mg/mL C16G2.

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Rinse
Description: Active rinses are 1.6 mg/mL C16G2.

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Rinse
Description: Active rinses are 1.6 mg/mL C16G2.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo is the vehicle without C16G2

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo is the vehicle without C16G2

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo is the vehicle without C16G2

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo is the vehicle without C16G2

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Gel
Description: Active C16G2 Gel is 3.2 mg/mL

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Gel
Description: Active C16G2 Gel is 3.2 mg/mL

Intervention type: DRUG
Group type: OTHER
Intervention: C16G2 Gel
Description: Active C16G2 Gel is 3.2 mg/mL
Study: NCT00759967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneurography
Description: Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneurography
Description: Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance testing
Description: bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance testing
Description: bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
Study: NCT03127124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NANT-008
Description: Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Injectable Product
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin Injectable Product
Description: Recombinant humanized monoclonal IgG1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium Injection
Description: Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eloxatin Injectable Product
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
Study: NCT03271437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-based Flash
Description: Progressive counting with Flash technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR-based Flash
Description: Eye movement desensitization and reprocessing with Flash technique
Study: NCT04257877

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples for proteomic analysis in plasma of both groups

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples for proteomic analysis in plasma of both groups
Study: NCT03527992

Intervention type: DEVICE
Group type: OTHER
Intervention: O2 automated
Description: In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates.

Intervention type: DEVICE
Group type: OTHER
Intervention: O2 standard
Description: In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care
Study: NCT03019497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Modules
Description: Educational session about a specific related problem

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
Study: NCT02732847

Intervention type: OTHER
Group type: OTHER
Intervention: A delayed prescription dated 2 days after clinical office visit

Intervention type: DRUG
Group type: OTHER
Intervention: Usual Dated
Study: NCT03243331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK7-ADC
Description: PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
Study: NCT00997997

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: 400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
Study: NCT01734746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracerinjection
Description: The intervention concerns the tracerinjection for detection of the sentinel node.
Study: NCT00965900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic band ligation
Description: * Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: * start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBL+Propranolol
Description: 1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
Study: NCT02370888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
Study: NCT00359762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral tablet (titrated to maximally tolerated dose), once daily
Study: NCT00621439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interfon Alpha 2B
Description: Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo.